International Prognostic Index
for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades.
An enhanced International Prognostic Index
(NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era.
Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic Index
The standard treatment for low to intermediate International Prognostic Index
(IPI) is R-CHOP.
Similarly with the introduction of Rituximab for management of DLCL-B, the significance of the International Prognostic Index
(see below) has been altered.
Most patients were in a low- to medium-risk group, according to risk factors from the International Prognostic Index
(for example, advanced stage, age >60, two or more extranodal sites).
And while risk status, assessed by the International Prognostic Index
(IPI), was rated favorable in the majority of patients, limited statistical analysis showed that patients with unfavorable IPI ratings also failed to benefit from HDC+ABMT.
Physicians currently assess a patient's DLBCL risk of disease progression and outcome by using the International Prognostic Index
(IPI), but more accurate classification of patients based on the underlying tumor biology is needed to allow physicians and patients to make more informed treatment decisions.
The secondary age-adjusted International Prognostic Index
score (saaIPI), early relapse <12 months after diagnosis, and prior rituximab treatment were reported to be independent factors affecting response rate after salvage therapy.
Objective: To determine the impact of Rituximab and international prognostic index
score on survival in diffuse large B-cell lymphoma patients.
The specific histologic type of the lymphoid neoplasm, stage of disease, as well as the International Prognostic Index
(IPI score) are the main factors used to determine treatment in adults.